SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD
SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Thoracic Oncology Consultation — Yul Brynner — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.
| Patient | Yul Brynner |
|---|
| Date of birth | 1920-07-11 |
|---|
| Identifiers | MRN HR-ML020-SYN-TD; SSN (made up) 000-20-4572 |
|---|
| Document date | 1983-09-15 |
|---|
| Author | Leah Morrow, MD |
|---|
| Custodian | St. Posthumous Health Center |
|---|
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Reason for Referral
Left upper lobe mass invading the mediastinum with mediastinal nodes and left vocal fold paralysis in a 63-year-old former heavy smoker. Please establish the diagnosis and stage, direct biomarker testing, and advise on first-line treatment. [S]
Urgency: Urgent, within two weeks. [S]
Questions for the consultant:
- What is the diagnosis and stage once the PET-CT, brain MRI, and biopsy are done, and is the lytic T10 lesion a metastasis?
- Is the biomarker testing complete enough to choose treatment (PD-L1 and comprehensive genomic profiling, tissue and plasma), and should treatment wait for it?
- What first-line systemic therapy do you recommend?
- Is there a role now for surgery, radiation, or a bone-modifying agent?
- What immune-related adverse event monitoring should primary care carry out, and what should prompt a call?
- How should palliative care, symptom management, and his wish to keep performing be built into the plan?
History of Present Illness
Mr. Brynner is seen at the request of Dr. Achterberg two weeks after he presented with six weeks of a weak, breathy voice. He is a stage actor and singer leading a touring production, which he has paused. He smoked about three packs a day from the age of 12 and quit 12 years ago. He has a mild morning cough, no hemoptysis, no chest, bone, or back pain, no headache, and no neurological symptoms, and his weight is steady after a small loss before presentation. He is fully active offstage but tires by evening. He has no autoimmune disease, organ transplant, or use of corticosteroids or other immunosuppressants. He wants the facts in full and wants to return to the stage. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
- Yul Brynner was born Yuliy Borisovich Bryner on July 11, 1920, in Vladivostok, Russia. [D]
- He gave varying accounts of his origins, saying at times that he was born on Sakhalin Island, with the year given as 1915 (UPI gives July 11, 1915; another reference gives July 12, 1915, under the name Taidje Kahn). [D]
- He first played the King of Siam in The King and I on Broadway in 1951, won the Academy Award for best actor in the 1956 film, and played the role 4,625 times over 34 years. [D]
- He smoked heavily for decades: UPI reported that at one time he smoked five packs of cigarettes a day, and Cancer Today reports two to four packs a day from the age of 12 and that he quit in 1971. [D]
- In September 1983 he was found to have lung cancer; Cancer Today reports that he had found a lump on his vocal cords and that the tumor was too close to his heart for surgery, and UPI reports that he was treated for lung cancer that month and said he would beat the disease and resume touring. [D]
4 later historical claims are omitted because they describe events after the index age. See the teaching note.
Allergies and Intolerances
| Allergy | Reaction | Status | Evidence |
|---|
| No known allergy | | active | S |
Problems
| Problem | Clinical status | Verification | Code | Provenance |
| Adenocarcinoma of the left upper lobe of the lung, stage IVB (cT4 N2 M1c, AJCC 8th edition), unresectable: the primary invades the mediastinum at the aortopulmonary window; bone metastases; PD-L1 tumor proportion score 70 percent (22C3); ECOG performance status 1; comprehensive genomic profiling results in the notes | active | confirmed |
C34.12 | S — Synthetic modern histology, stage, and biomarkers linked to his documented inoperable lung cancer of September 1983. |
| Bone metastases at T10, the right ilium, and the left sixth rib on PET-CT, without pain, fracture, or cord compression | active | confirmed |
C79.51 | S — Synthetic metastatic sites chosen so that first-line systemic therapy is the standard of care; no source describes the spread of his cancer. |
| Left vocal fold paralysis with a breathy, weak voice, most likely from left recurrent laryngeal nerve involvement by disease in the aortopulmonary window | active | confirmed |
J38.01 | S — Synthetic laryngoscopy finding anchored to the published account that a vocal-cord problem led to his diagnosis; the lay 'lump on his vocal cords' is not modeled as a laryngeal tumor. |
| Left upper lobe mass invading the mediastinum, with enlarged mediastinal lymph nodes, on CT at presentation; suspicious for lung cancer pending tissue diagnosis | active | confirmed |
R91.8 | S — Synthetic presenting imaging finding, recorded before the tissue diagnosis. |
| Former smoker: about 3 packs a day from age 12 until he quit 12 years ago, roughly 115 pack-years; no tobacco since | active | confirmed |
Z87.891 | S — Synthetic modern entry linked to the documented heavy smoking and quitting; the pack-year figure is a synthetic midpoint of conflicting published amounts. |
Physical Exam
Vital signs recorded on 1983-09-15; see the referring visit's Vital Signs section. [S]
| System | Finding |
|---|
| General | Upright and composed; ECOG 1; weight 72.0 kg |
| Voice | Breathy, low-volume voice |
| Lymph nodes | No supraclavicular or cervical nodes |
| Lungs | Slightly reduced breath sounds at the left apex |
| Spine and pelvis | No tenderness over T10, the ribs, or the right iliac crest |
| Neurological | Normal strength, sensation, and gait |
Results
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
| 1983-09-15 | Total score [Edmonton Symptom Assessment System] | 18 | {score} | | | S |
Assessment
- Adenocarcinoma of the left upper lobe, stage IVB (cT4 N2 M1c) (C34.12). Adenocarcinoma, TTF-1 and napsin A positive, from subcarinal and 4L nodes. The primary invades the mediastinum (T4), the aortopulmonary window and subcarinal nodes are involved (N2), and PET-CT shows avid lytic lesions at T10, the right ilium, and the left sixth rib (M1c, stage IVB). Several typical avid lytic lesions do not need biopsy, because confirming one would not change treatment. The brain MRI is clear. The tumor is not resectable and not curable with surgery or chemoradiation; treatment aims at control, symptom relief, and time. [S]
- Biomarkers. PD-L1 (22C3) tumor proportion score 70 percent. Plasma testing shows no actionable alteration, but a negative plasma result does not exclude a driver, so tissue sequencing (EGFR, ALK, ROS1, BRAF, KRAS G12C, MET exon 14, RET, NTRK, HER2, NRG1) must be reviewed before an immune checkpoint inhibitor is started: starting one before a targetable driver is found can raise the toxicity of later targeted therapy and gives less benefit. The result is expected within a week, so waiting costs little. [S]
- First-line therapy. If no actionable alteration is found, NCCN lists pembrolizumab alone, or pembrolizumab with carboplatin and pemetrexed, among the preferred first-line options for PD-L1 50 percent or more. With ECOG 1, no visceral crisis, and his wish to keep his energy and voice for the stage, pembrolizumab 200 mg every 3 weeks is recommended, with chemotherapy added at progression. He has no autoimmune or transplant history that would argue against immunotherapy. After the first response scan, 400 mg every 6 weeks would fit touring. [S]
- Bone metastases (C79.51). No pain, fracture, or threatened cord, so no radiation is needed now. A bone-modifying agent reduces skeletal events: zoledronic acid 4 mg every 12 weeks after a dental examination, with calcium and vitamin D. Palliative radiation if a lesion becomes painful or threatens fracture. [S]
- Left vocal fold paralysis (J38.01). Caused by recurrent laryngeal nerve involvement in the aortopulmonary window. Radiation is unlikely to restore nerve function; injection medialization and voice therapy offer the best chance of a stage-worthy voice. [S]
Data reviewed: Laryngoscopy; CT of the chest, abdomen, and pelvis; FDG PET-CT and brain MRI eleven days ago; endobronchial ultrasound needle aspiration six days ago with cytology, immunohistochemistry, and PD-L1; plasma cell-free DNA sequencing; intake laboratory results. [S]
Plan of Treatment
- Wait for tissue sequencing, expected within a week; if it shows no actionable alteration, start pembrolizumab 200 mg every 3 weeks. [S]
- Baseline TSH, free T4, morning cortisol, liver tests, glucose, creatinine, and blood count; then TSH, free T4, liver tests, glucose, creatinine, and blood count before each infusion, with cortisol for fatigue, dizziness, low blood pressure, or low sodium. [S]
- Give him a written list of warning symptoms (diarrhea, new cough or breathlessness, rash, yellowing, severe fatigue, headache, or dizziness) and the 24-hour oncology telephone line; primary care should call oncology the same day for any of them and should not start corticosteroids without discussion, except in an emergency. [S]
- Response CT of the chest, abdomen, and pelvis about nine weeks after starting, then every 6 to 12 weeks. [S]
- Dental examination, then zoledronic acid 4 mg every 12 weeks with calcium and vitamin D; start it with the second cycle so that a first-dose reaction is not confused with an early immune-related event. [S]
- Early palliative care within the next few weeks, alongside treatment, with symptom and distress screening at every visit. [S]
- Injection medialization and voice therapy, and a graded return to performing as he chooses, with infusions scheduled around his work. [S]
- No surgery and no radiation now. [S]
- Discussed with Dr. Achterberg the same day; the patient agrees and asked that treatment fit his return to the stage. [S]
- Follow-up: Thoracic oncology will see him next week with the tissue sequencing result to start treatment, and at each cycle. Primary care will continue the CMID lung cancer monitoring, preventive care, and coordination with palliative care. [S]